COMPANY

Teclison

HQ: Princeton, NJ (US office) source · teclison.com ↗

Keywords: oncology cancer advanced hepatocellular carcinoma Gastrointestinal Cancer Metastatic Neuroendocrine Tumors Colorectal Cancer Lung Cancer Gastric Cancer Tirapazamine

Location: Princeton, NJ (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

May 20, 2021 Trial start Phase 2: TATE and Pembrolizumab (MK3475) in mCRC and NSCLC source ↗
Dec 5, 2017 Trial start Phase 2: TATE Versus TACE in Intermediate Stage HCC source ↗
Jul 1, 2017 Trial start Phase 2: Combination of TATE and PD-1 Inhibitor in Liver Cancer source ↗
2014-09 Trial start Phase 1/Phase 2: Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer source ↗

Upcoming milestones

Dec 30, 2026 (ESTIMATED) · Phase 2 · Combination of TATE and PD-1 Inhibitor in Liver Cancer · NCT03259867
Mar 31, 2027 (ESTIMATED) · Phase 2 · TATE and Pembrolizumab (MK3475) in mCRC and NSCLC · NCT04701476
Mar 31, 2028 (ESTIMATED) · Phase 1/Phase 2 · Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer · NCT02174549

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT02174549	Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer	Phase 1/Phase 2	Recruiting	2014-09	Mar 31, 2028 (estimated)
NCT04701476	TATE and Pembrolizumab (MK3475) in mCRC and NSCLC	Phase 2	Recruiting	May 20, 2021	Mar 31, 2027 (estimated)
NCT03259867	Combination of TATE and PD-1 Inhibitor in Liver Cancer	Phase 2	Recruiting	Jul 1, 2017	Dec 30, 2026 (estimated)
NCT03145558	TATE Versus TACE in Intermediate Stage HCC	Phase 2	Terminated	Dec 5, 2017	Jun 30, 2024 (actual)